Eintrag weiter verarbeiten
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis
Gespeichert in:
| Zeitschriftentitel: | Thoracic Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Thoracic Cancer, 10, 2019, 9, S. 1819-1826 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Nagy, Attila Müller, Veronika Kolonics‐Farkas, Abigel M. Eszes, Noemi Vincze, Krisztina Horvath, Gabor Nagy, Attila Müller, Veronika Kolonics‐Farkas, Abigel M. Eszes, Noemi Vincze, Krisztina Horvath, Gabor |
|---|---|
| author |
Nagy, Attila Müller, Veronika Kolonics‐Farkas, Abigel M. Eszes, Noemi Vincze, Krisztina Horvath, Gabor |
| spellingShingle |
Nagy, Attila Müller, Veronika Kolonics‐Farkas, Abigel M. Eszes, Noemi Vincze, Krisztina Horvath, Gabor Thoracic Cancer Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis Pulmonary and Respiratory Medicine Oncology General Medicine |
| author_sort |
nagy, attila |
| spelling |
Nagy, Attila Müller, Veronika Kolonics‐Farkas, Abigel M. Eszes, Noemi Vincze, Krisztina Horvath, Gabor 1759-7706 1759-7714 Wiley Pulmonary and Respiratory Medicine Oncology General Medicine http://dx.doi.org/10.1111/1759-7714.13153 <jats:sec><jats:title>Background</jats:title><jats:p>Pulmonary malignancy is one of the most frequent and fatal cancers in older patients. As data on lower respiratory tract infection (LRTI) and the outcome of lung cancer are scarce, our objective was to determine the impact of LRTI on therapeutic possibilities and one‐year mortality.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients undergoing bronchoscopy in 2017 who had bronchial microbial sampling at the time of the lung cancer diagnosis (<jats:italic>n</jats:italic> = 143) were included. Group 1 (LRTI+) included patients with confirmed infection (<jats:italic>n</jats:italic> = 74) while Group 2 (LRTI‐) included patients without infection (<jats:italic>n</jats:italic> = 69). Clinical characteristics, pathogen profile and one‐year survival were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Age, gender, TNM stage, histology type, comorbidities or underlying lung disease did not differ among groups. The most common LRTI pathogens included aerobic (<jats:italic>n</jats:italic> = 49), anaerobic (<jats:italic>n</jats:italic> = 14) and fungal (<jats:italic>n</jats:italic> = 26) infections. Chemo/immune/target therapy alone, or in combination with radiotherapy were significantly less frequently used, whilst palliative care was more common in Group 1 (LRTI+). Multiple pathogen LRTI patients were significantly older, less frequently diagnosed with adenocarcinoma and had worse performance status compared to solitary pathogen LRTI patients. One‐year median survival was 274 days (235 vs. 305 days Group 1 vs. Group 2). Risk factors for increased one‐year mortality included performance status ≥2 (OR 30.00, CI 95% 5.23–313.00), performance status 1 (OR 11.87, CI 95% 4.12–33.78), male gender (OR 4.04, CI 2.03–8.04), LRTI with multiple pathogens (OR 2.72, CI 1.01–6.81) and nonadenocarcinoma histology (OR 2.26, CI 1.15–4.56).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>LRTIs in lung cancer patients, especially multiple pathogen infections, are associated with less oncotherapeutic possibilities and significant risk for lower one‐year median survival.</jats:p></jats:sec> Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis Thoracic Cancer |
| doi_str_mv |
10.1111/1759-7714.13153 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS8xNzU5LTc3MTQuMTMxNTM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS8xNzU5LTc3MTQuMTMxNTM |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
1759-7706 1759-7714 |
| issn_str_mv |
1759-7706 1759-7714 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
nagy2019worselungcanceroutcomeinpatientswithlowerrespiratorytractinfectionconfirmedattimeofdiagnosis |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Thoracic Cancer |
| source_id |
49 |
| title |
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_unstemmed |
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_full |
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_fullStr |
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_full_unstemmed |
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_short |
Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_sort |
worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| topic |
Pulmonary and Respiratory Medicine Oncology General Medicine |
| url |
http://dx.doi.org/10.1111/1759-7714.13153 |
| publishDate |
2019 |
| physical |
1819-1826 |
| description |
<jats:sec><jats:title>Background</jats:title><jats:p>Pulmonary malignancy is one of the most frequent and fatal cancers in older patients. As data on lower respiratory tract infection (LRTI) and the outcome of lung cancer are scarce, our objective was to determine the impact of LRTI on therapeutic possibilities and one‐year mortality.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients undergoing bronchoscopy in 2017 who had bronchial microbial sampling at the time of the lung cancer diagnosis (<jats:italic>n</jats:italic> = 143) were included. Group 1 (LRTI+) included patients with confirmed infection (<jats:italic>n</jats:italic> = 74) while Group 2 (LRTI‐) included patients without infection (<jats:italic>n</jats:italic> = 69). Clinical characteristics, pathogen profile and one‐year survival were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Age, gender, TNM stage, histology type, comorbidities or underlying lung disease did not differ among groups. The most common LRTI pathogens included aerobic (<jats:italic>n</jats:italic> = 49), anaerobic (<jats:italic>n</jats:italic> = 14) and fungal (<jats:italic>n</jats:italic> = 26) infections. Chemo/immune/target therapy alone, or in combination with radiotherapy were significantly less frequently used, whilst palliative care was more common in Group 1 (LRTI+). Multiple pathogen LRTI patients were significantly older, less frequently diagnosed with adenocarcinoma and had worse performance status compared to solitary pathogen LRTI patients. One‐year median survival was 274 days (235 vs. 305 days Group 1 vs. Group 2). Risk factors for increased one‐year mortality included performance status ≥2 (OR 30.00, CI 95% 5.23–313.00), performance status 1 (OR 11.87, CI 95% 4.12–33.78), male gender (OR 4.04, CI 2.03–8.04), LRTI with multiple pathogens (OR 2.72, CI 1.01–6.81) and nonadenocarcinoma histology (OR 2.26, CI 1.15–4.56).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>LRTIs in lung cancer patients, especially multiple pathogen infections, are associated with less oncotherapeutic possibilities and significant risk for lower one‐year median survival.</jats:p></jats:sec> |
| container_issue |
9 |
| container_start_page |
1819 |
| container_title |
Thoracic Cancer |
| container_volume |
10 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334556232155140 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:30:32.278Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Worse+lung+cancer+outcome+in+patients+with+lower+respiratory+tract+infection+confirmed+at+time+of+diagnosis&rft.date=2019-09-01&genre=article&issn=1759-7714&volume=10&issue=9&spage=1819&epage=1826&pages=1819-1826&jtitle=Thoracic+Cancer&atitle=Worse+lung+cancer+outcome+in+patients+with+lower+respiratory+tract+infection+confirmed+at+time+of+diagnosis&aulast=Horvath&aufirst=Gabor&rft_id=info%3Adoi%2F10.1111%2F1759-7714.13153&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334556232155140 |
| author | Nagy, Attila, Müller, Veronika, Kolonics‐Farkas, Abigel M., Eszes, Noemi, Vincze, Krisztina, Horvath, Gabor |
| author_facet | Nagy, Attila, Müller, Veronika, Kolonics‐Farkas, Abigel M., Eszes, Noemi, Vincze, Krisztina, Horvath, Gabor, Nagy, Attila, Müller, Veronika, Kolonics‐Farkas, Abigel M., Eszes, Noemi, Vincze, Krisztina, Horvath, Gabor |
| author_sort | nagy, attila |
| container_issue | 9 |
| container_start_page | 1819 |
| container_title | Thoracic Cancer |
| container_volume | 10 |
| description | <jats:sec><jats:title>Background</jats:title><jats:p>Pulmonary malignancy is one of the most frequent and fatal cancers in older patients. As data on lower respiratory tract infection (LRTI) and the outcome of lung cancer are scarce, our objective was to determine the impact of LRTI on therapeutic possibilities and one‐year mortality.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients undergoing bronchoscopy in 2017 who had bronchial microbial sampling at the time of the lung cancer diagnosis (<jats:italic>n</jats:italic> = 143) were included. Group 1 (LRTI+) included patients with confirmed infection (<jats:italic>n</jats:italic> = 74) while Group 2 (LRTI‐) included patients without infection (<jats:italic>n</jats:italic> = 69). Clinical characteristics, pathogen profile and one‐year survival were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Age, gender, TNM stage, histology type, comorbidities or underlying lung disease did not differ among groups. The most common LRTI pathogens included aerobic (<jats:italic>n</jats:italic> = 49), anaerobic (<jats:italic>n</jats:italic> = 14) and fungal (<jats:italic>n</jats:italic> = 26) infections. Chemo/immune/target therapy alone, or in combination with radiotherapy were significantly less frequently used, whilst palliative care was more common in Group 1 (LRTI+). Multiple pathogen LRTI patients were significantly older, less frequently diagnosed with adenocarcinoma and had worse performance status compared to solitary pathogen LRTI patients. One‐year median survival was 274 days (235 vs. 305 days Group 1 vs. Group 2). Risk factors for increased one‐year mortality included performance status ≥2 (OR 30.00, CI 95% 5.23–313.00), performance status 1 (OR 11.87, CI 95% 4.12–33.78), male gender (OR 4.04, CI 2.03–8.04), LRTI with multiple pathogens (OR 2.72, CI 1.01–6.81) and nonadenocarcinoma histology (OR 2.26, CI 1.15–4.56).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>LRTIs in lung cancer patients, especially multiple pathogen infections, are associated with less oncotherapeutic possibilities and significant risk for lower one‐year median survival.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/1759-7714.13153 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS8xNzU5LTc3MTQuMTMxNTM |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1759-7706, 1759-7714 |
| issn_str_mv | 1759-7706, 1759-7714 |
| language | English |
| last_indexed | 2024-03-01T14:30:32.278Z |
| match_str | nagy2019worselungcanceroutcomeinpatientswithlowerrespiratorytractinfectionconfirmedattimeofdiagnosis |
| mega_collection | Wiley (CrossRef) |
| physical | 1819-1826 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Thoracic Cancer |
| source_id | 49 |
| spelling | Nagy, Attila Müller, Veronika Kolonics‐Farkas, Abigel M. Eszes, Noemi Vincze, Krisztina Horvath, Gabor 1759-7706 1759-7714 Wiley Pulmonary and Respiratory Medicine Oncology General Medicine http://dx.doi.org/10.1111/1759-7714.13153 <jats:sec><jats:title>Background</jats:title><jats:p>Pulmonary malignancy is one of the most frequent and fatal cancers in older patients. As data on lower respiratory tract infection (LRTI) and the outcome of lung cancer are scarce, our objective was to determine the impact of LRTI on therapeutic possibilities and one‐year mortality.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients undergoing bronchoscopy in 2017 who had bronchial microbial sampling at the time of the lung cancer diagnosis (<jats:italic>n</jats:italic> = 143) were included. Group 1 (LRTI+) included patients with confirmed infection (<jats:italic>n</jats:italic> = 74) while Group 2 (LRTI‐) included patients without infection (<jats:italic>n</jats:italic> = 69). Clinical characteristics, pathogen profile and one‐year survival were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Age, gender, TNM stage, histology type, comorbidities or underlying lung disease did not differ among groups. The most common LRTI pathogens included aerobic (<jats:italic>n</jats:italic> = 49), anaerobic (<jats:italic>n</jats:italic> = 14) and fungal (<jats:italic>n</jats:italic> = 26) infections. Chemo/immune/target therapy alone, or in combination with radiotherapy were significantly less frequently used, whilst palliative care was more common in Group 1 (LRTI+). Multiple pathogen LRTI patients were significantly older, less frequently diagnosed with adenocarcinoma and had worse performance status compared to solitary pathogen LRTI patients. One‐year median survival was 274 days (235 vs. 305 days Group 1 vs. Group 2). Risk factors for increased one‐year mortality included performance status ≥2 (OR 30.00, CI 95% 5.23–313.00), performance status 1 (OR 11.87, CI 95% 4.12–33.78), male gender (OR 4.04, CI 2.03–8.04), LRTI with multiple pathogens (OR 2.72, CI 1.01–6.81) and nonadenocarcinoma histology (OR 2.26, CI 1.15–4.56).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>LRTIs in lung cancer patients, especially multiple pathogen infections, are associated with less oncotherapeutic possibilities and significant risk for lower one‐year median survival.</jats:p></jats:sec> Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis Thoracic Cancer |
| spellingShingle | Nagy, Attila, Müller, Veronika, Kolonics‐Farkas, Abigel M., Eszes, Noemi, Vincze, Krisztina, Horvath, Gabor, Thoracic Cancer, Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis, Pulmonary and Respiratory Medicine, Oncology, General Medicine |
| title | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_full | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_fullStr | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_full_unstemmed | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_short | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_sort | worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| title_unstemmed | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| topic | Pulmonary and Respiratory Medicine, Oncology, General Medicine |
| url | http://dx.doi.org/10.1111/1759-7714.13153 |